Blueprint Medicines Overview
Blueprint Medicines (BPMC) has a PEG ratio of 121.67, above the Healthcare sector average of 1.26.
Get informed when a big investor buys or sells
+ Follow121.67
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for BPMC is 121.67. That is above the Healthcare sector average of 1.26. Investors often review this figure alongside Blueprint Medicines's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, BPMC currently prints 121.67 for PEG ratio, while the sector average sits near 1.26. That is roughly 9577.3% above the sector mean. Large gaps often invite a closer look at Blueprint Medicines's growth, margins, and balance sheet.
A PEG ratio of 121.67 for Blueprint Medicines is not 'good' or 'bad' on its own. Compare it with the peer average (1.26) and with BPMC's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting BPMC's PEG ratio (121.67), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Blueprint Medicines's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
